Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation.
Journal
Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676
Informations de publication
Date de publication:
28 Nov 2023
28 Nov 2023
Historique:
received:
23
05
2023
revised:
15
08
2023
accepted:
14
11
2023
medline:
30
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
ppublish
Résumé
In the general population, physical activity has been associated with a lower risk of several cancers; however, the evidence for ovarian cancer is not clear. It is suggested that early-life physical activity may differentially impact risk. Whether this is true among women at high risk due to a pathogenic variant (mutation) in the BRCA1 or BRCA2 genes has not been evaluated. Thus, we performed a matched case-control study to evaluate the association between adolescent and early-adulthood physical activity and ovarian cancer. BRCA mutation carriers who completed a research questionnaire on various exposures and incident disease and with data available on physical activity were eligible for inclusion. Self-reported activity at ages 12-13, 14-17, 18-22, 23-29, and 30-34 was used to calculate the average metabolic equivalent of task (MET)-hours/week for moderate, vigorous, and total physical activity during adolescence (ages 12-17) and early-adulthood (ages 18-34). Conditional logistic regression was used to estimate the OR and 95% confidence intervals (CI) of invasive ovarian cancer associated with physical activity. This study included 215 matched pairs (mean age = 57.3). There was no association between total physical activity during adolescence (ORhigh vs. low = 0.91; 95% CI: 0.61-1.36; Ptrend = 0.85), early-adulthood (ORhigh vs. low = 0.78; 95% CI: 0.51-1.20; Ptrend = 0.38) and overall (ORhigh vs. low = 0.81; 95% CI: 0.54-1.23; Ptrend = 0.56) and ovarian cancer. Findings were similar for moderate (Ptrend ≥ 0.25) and vigorous (Ptrend ≥ 0.57) activity. These findings do not provide evidence for an association between early-life physical activity and BRCA-ovarian cancer; however, physical activity should continue to be encouraged to promote overall health. In this matched case-control study, we observed no association between physical activity during adolescence or early-adulthood and subsequent risk of ovarian cancer. These findings do not provide evidence for an association between early-life physical activity and BRCA-ovarian cancer; however, being active remains important to promote overall health and well-being.
Identifiants
pubmed: 38019076
pii: 731420
doi: 10.1158/2767-9764.CRC-23-0223
pmc: PMC10683556
doi:
Substances chimiques
BRCA1 protein, human
0
BRCA1 Protein
0
BRCA2 protein, human
0
BRCA2 Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2420-2429Subventions
Organisme : CCS | Canadian Cancer Society Research Institute (CCSRI)
ID : 703058
Organisme : Peter Gilgan Foundation (The Peter Gilgan Foundation)
Organisme : CIHR Canada Graduate Scholarships Doctoral Award
Organisme : Tier II Canada Research Chair
Organisme : Sondra J and Stephen R Hardis Endowed Chair of Cancer Genomic Medicine
Organisme : Tier I Canada Research Chair
Informations de copyright
© 2023 The Authors; Published by the American Association for Cancer Research.
Références
Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2321-30
pubmed: 18006921
Med Sci Sports Exerc. 2011 Aug;43(8):1575-81
pubmed: 21681120
Obstet Gynecol. 2000 Oct;96(4):609-14
pubmed: 11004368
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Br J Cancer. 1987 Jun;55(6):681-5
pubmed: 3620313
Carcinogenesis. 2022 Apr 25;43(3):231-242
pubmed: 34958358
Int J Cancer. 2006 Jun 15;118(12):3153-60
pubmed: 16425259
Int J Cancer. 2016 Feb 15;138(4):843-52
pubmed: 26335147
Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):2038-2043
pubmed: 34426412
Cancer Causes Control. 2010 Dec;21(12):2183-94
pubmed: 20827504
Lancet Oncol. 2013 Nov;14(12):1226-32
pubmed: 24140203
Gynecol Oncol. 2020 Dec;159(3):820-826
pubmed: 33010967
Am J Prev Med. 2022 Nov;63(5):837-845
pubmed: 35738959
Int J Epidemiol. 1994 Oct;23(5):991-9
pubmed: 7860180
Int J Cancer. 2020 Apr 1;146(7):1800-1809
pubmed: 31199510
Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2000-8
pubmed: 23966580
Lancet. 2021 Jun 5;397(10290):2182-2193
pubmed: 33991479
J Natl Compr Canc Netw. 2017 Jan;15(1):9-20
pubmed: 28040716
Int J Cancer. 2001 Feb 1;91(3):407-11
pubmed: 11169967
J Natl Cancer Inst. 1998 Dec 2;90(23):1774-86
pubmed: 9839517
CA Cancer J Clin. 2022 May;72(3):230-262
pubmed: 35294043
JNCI Cancer Spectr. 2019 Oct 17;4(1):pkz080
pubmed: 32337494
Int J Cancer. 2002 May 20;99(3):431-6
pubmed: 11992414
Cancer Causes Control. 2010 Apr;21(4):485-91
pubmed: 19953315
Eur J Epidemiol. 2004;19(11):1011-9
pubmed: 15648594
Eur J Cancer Prev. 2009 Aug;18(4):322-30
pubmed: 19390450
Med Sci Sports Exerc. 2019 Jun;51(6):1252-1261
pubmed: 31095082
Breast Cancer Res. 2015 Nov 05;17(1):139
pubmed: 26541144
Int J Cancer. 2021 Dec 15;149(12):2045-2051
pubmed: 34398976
Hered Cancer Clin Pract. 2020 Mar 07;18:5
pubmed: 32165993
Gynecol Oncol. 2018 Jul;150(1):85-91
pubmed: 29793803
Gynecol Oncol. 2015 Jun;137(3):559-73
pubmed: 25797080